<DOC>
	<DOCNO>NCT00392574</DOCNO>
	<brief_summary>The objective pivotal Phase III study investigate safety efficacy prulifloxacin versus placebo treatment subject acute bacterial gastroenteritis .</brief_summary>
	<brief_title>Safety Efficacy Prulifloxacin Versus Placebo Traveler 's Diarrhea</brief_title>
	<detailed_description>This double-blind trial compare safety efficacy prulifloxacin versus placebo adult traveler acute gastroenteritis characterize diarrhea one follow sign symptom : nausea , vomit , abdominal pain cramping , fecal urgency , moderate severe gas-related symptom , tenesmus â‰¤72 hour duration .</detailed_description>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Prulifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>Diagnosis Acute Bacterial Gastroenteritis ; Traveler Industrialized Country ; Capable give Informed Consent Fever ( &gt; 100.3 degree ) ; Pregnant Breast Feeding Not use adequate birth control ; Known Suspected ( co ) Infection nonbacterial pathogen ; Symptoms Gastroenteritis &gt; 72 hour ; Bloody Diarrhea ; Concomitant antibacterial activity enteric bacterial pathogen ; History IBD ; Unable/Unwilling comply study protocol ; &gt; 2 dos antidiarrheal medication within 24 hour ; Antimicrobial Treatment within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Gastroenteritis</keyword>
</DOC>